EGFR and non-small cell lung carcinoma: There was no heterogeneity in OS or PFS between the two studies which reported the data in that subgroup; therefore, FEM was applied for the comparison of the group of EGFR TKI administration between chemotherapy cycles and the EGFR TKI monotherapy group (OS, I2 = 0%, P = 0.695; PFS, I2 = 0%, P = 0.547); for the NSCLC patients with wild-type EGFR, OS and PFS were similar between these two treatment groups (OS, HR = 0.70, 95% CI: 0.46–1.05, P = 0.084; PFS, HR = 1.36, 95% CI: 0.80–2.31, P = 0.260) (Fig. 6A).